Page last updated: 2024-11-12

destruxin a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

destruxin A: cyclopeptide from entomopathogenic fungus Metarhyzium anisopliae; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID91746256
MeSH IDM0120381

Synonyms (3)

Synonym
destruxin a
cyclo[n-methyl-l-alanyl-.beta.-alanyl-(2r)-2-hydroxy-4-pentenoyl-l-prolyl-l-isoleucyl-n-methyl-l-valyl]
XIYSEKITPHTMJT-HFWOUJIZSA-N

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" charged radicals (COO-) appear the least toxic probably because they do not penetrate easily the cellular membranes."( Insecticidal and cytotoxic effects of natural and hemisynthetic destruxins.
Dumas, C; Pais, M; Quiot, JM; Robert, P; Vey, A, 1994
)
0.29
" Evaluation of the cytotoxic activity of these different compounds suggested that a wide range of metabolites with synergistic or adverse effects are present in the crude extract."( Toxicity testing of destruxins and crude extracts from the insect-pathogenic fungus Metarhizium anisopliae.
Butt, TM; Skrobek, A, 2005
)
0.33
" An MTT assay showed that DA was highly toxic to SL-1 cells in a concentration- and time-dependent manner."( Toxicity and differential protein analysis following destruxin A treatment of Spodoptera litura (Lepidoptera: Noctuidae) SL-1 cells.
Hu, J; Hu, Q; Jin, F; Meng, X; Ren, S; Sun, Q; Xu, X; Yu, X, 2011
)
0.37
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (52)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (1.92)18.7374
1990's9 (17.31)18.2507
2000's12 (23.08)29.6817
2010's26 (50.00)24.3611
2020's4 (7.69)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (1.79%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other55 (98.21%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]